Trial · NCT07374029
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
NCT07374029, Phase 1, Recruiting, David Avigan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML. Trials, record NCT07374029. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07374029
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
- NCT number
- NCT07374029
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- David Avigan
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Interventions
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
- First posted
- 2026-01-28
- Last updated
- 2026-05-05
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful Manufacture and Administration Rate of Vaccine-Educated T Cells | 28 weeks | Successful manufacture and administration rate is defined as the proportion of enrolled participants for whom autologous vaccine-educated T cells are successfully manufactured and administered per protocol. |
| Primary | Maximum Tolerated Dose (MTD) of Vaccine-Educated T Cells | 56 Days | The MTD is defined as the highest dose level that one or fewer participants experiences a dose-limiting toxicity (DLT) or one dose level below the maximum administered dose level where two or more participants experience a DLT. |
| Primary | Toxicity Rate of Vaccine-Educated T Cells, Including CRS, Neurotoxicity, and Infections | 5 years | Toxicity rate of vaccine-educated T cells is defined as the proportion of participants who experience at least one toxicity, including cytokine release syndrome, neurotoxicity, or infections, out of all participants who receive at least one T-cell infusion. |
| Secondary | Relapse-Free Survival (RFS) at 1 Year Post Administration of Vaccine Educated T Cells | 1 year | RFS based on Kaplan-Meier method is defined as the time from the first T-cell infusion to the first documented disease relapse or death from any cause. Participants without relapse will be censored at the last disease assessment. Relapse is defined as the reappearance of blasts in the blood, or a bone marrow aspirate and biopsy showing \>5% blasts, not attributable to another cause. If there are no circulating blasts, a repeat bone marrow performed \>1 week later documenting more than 5% blasts is necessary to meet criteria for relapse. |
| Secondary | Relapse-Free Survival (RFS) at 2 Years Post Administration of Vaccine Educated T Cells | 2 years | RFS based on Kaplan-Meier method is defined as the time from the first T-cell infusion to the first documented disease relapse or death from any cause. Participants without relapse will be censored at the last disease assessment. Relapse is defined as the reappearance of blasts in the blood, or a bone marrow aspirate and biopsy showing \>5% blasts, not attributable to another cause. If there are no circulating blasts, a repeat bone marrow performed \>1 week later documenting more than 5% blasts is necessary to meet criteria for relapse. |
| Secondary | MRD Negative Conversion Rate | MRD samples are collected up to 6 months after the last cell therapy dose. | MRD negative conversion rate is defined as the proportion of participants who convert from MRD-positive status at baseline to MRD-negative status at a subsequent post-baseline assessment, |
| Secondary | Median Overall Survival (OS) | 5 years | Overall survival (OS), estimated using the Kaplan-Meier method, is defined as the time from registration to death from any cause. Participants without a death event will be censored at the last date they are known to be alive. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07374029
GET https://conductscience.org/api/trials/v1/NCT07374029/registered